Clinical trials: Gastro-Intestinal Disorders
Colorectal Cancer, Triple Negative Breast Cancer
A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)
The purpose of this trial is to evaluate changes in immune activity relative to baseline following treatment with Toca 511 and Toca FC in patients with solid tumors (including recurrent high grade glioma [rHGG]) or lymphoma.
- Conditions
- Colorectal Cancer, Triple Negative Breast Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer
- Trial name
- NCT02576665
- Testing
- Toca 511, Toca FC
- Where
- 3 sites in United States
- Volunteers
- 21 people
- Sponsor
- Tocagen Inc.
Gastro-Intestinal Disorder
A Study to Compare and Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of UI059 and UIC202201
A randomized, open-label, multiple-dose crossover phase 1 clinical trial to compare and evaluate the safety, pharmacokinetics and pharmacodynamics characteristics after oral administration of UI059 and UIC202201 in healthy adult…
- Trial name
- NCT06393881
- Testing
- UI059, UIC202201
- Where
- South Korea
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Korea United Pharm. Inc.
Bladder Cancer, Glioma
Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer
The objective of this study is to assess two novel positron emission tomography (PET) radiotracers, [64Cu]CM500 and [68Ga]CM500, for Positron Emission Tomography-Magnetic Resonance Imaging (PET-MR) and Positron Emission…
- Conditions
- Bladder Cancer, Glioma, Glioblastoma (GBM), Breast Cancer
- Trial name
- NCT07781852
- Testing
- [64Cu]CM500, [68Ga]CM500, PET/MR
- Where
- 3 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Lumina Pharmaceuticals Inc
Colorectal Neoplasms, Stomach Neoplasms
SND002 Cell Injection in Participants With Advanced Malignant Solid Tumors
This is a phase 1, multicenter, open-label, single-arm study evaluating SND002 Cell Injection in participants with advanced malignant solid tumors that have progressed after standard treatment or for whom no standard treatment is…
- Conditions
- Colorectal Neoplasms, Stomach Neoplasms, Solid Tumor Malignancies
- Trial name
- NCT07903857
- Testing
- SND002 Cell Injection
- Where
- 2 sites in China
- Volunteers
- 78 people
- Sponsor
- Guizhou Sinorda Pharmaceutical Co., Ltd.
EBV Associated Extranodal NK/T-cell Lymphoma, EBV-Associated GastricCarcinoma or Esophageal AdenoCarcinoma
A Multi-center, Single-arm, Open, Phase I/IIa Clinical Trial to Evaluate the Efficacy and Safety of EBViNT Cell (EBV Specific Autologous CD8+ T Cell) in Patients With Treatment Failed Epstein Barr Virus (EBV)-Positive Malignancies
The present study is a multi-center, single-arm, open, phase I/IIa clinical trial to evaluate the efficacy and safety of EBViNT Cell when administered to patients with Epstein-Barr (EBV) positive malignancies The present study…
- Trial name
- NCT03789617
- Testing
- EBViNT Cell
- Where
- 8 sites in South Korea
- Volunteers
- 72 people
- Sponsor
- Eutilex
Gastroesophageal Reflux Disease
PH Metry Study to Compare the Antacid Activity of Z0063 Versus Gaviscon Double Action Tablets, in Healthy Adult Subjects
Primary Objective: Pharmacodynamics: assessment by pH metry of the change in gastric pH (antacid activity) of Z0063, in comparison to the effect of Gaviscon Double Action Tablets, in healthy adult subjects.
- Trial name
- NCT03069963
- Testing
- Z0063, Gaviscon
- Where
- France
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Sanofi
Stage III Colorectal Cancer, Neutropenia
A Trial of MB-6 for Reduction of Neutropenia Induced by Chemotherapy in Patients With Stage III Colorectal Cancer.
This is a randomized, double-blind, placebo-controlled multi-center phaseⅢstudy to evaluate efficacy and safety of oxaliplatin-based chemotherapy plus MB-6(320 mg/capsule, 6 capsules tid) in patients with stage 3 colorectal…
- Trial name
- MB-6 (NCT02135887)
- Testing
- MB-6
- Where
- Taiwan
- Volunteers
- 184 people
- Sponsor
- Microbio Co Ltd
Solid Tumors (Pancreatic Cancer, Esophageal Cancer, Gastric Cancer, Cholangiocarcinoma, Lung Cancer and Ovarian Cancer)
An Exploratory Clinical Study to Evaluate the Safety and Efficacy of NK Cells (Combined With Standard Therapy) in the Treatment of Solid Tumor Patients
An exploratory clinical study to evaluate the safety and efficacy of NK cells (combined with standard therapy) in the treatment of solid tumor patients
- Trial name
- CCT-ANK-11 (NCT06284226)
- Testing
- Allogeneic NK（CCT-ANK-11)
- Sponsor
- Beijing Kejing Biotechnology Co., Ltd.
Eosinophilic Esophagitis (EoE)
A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitis
This study is researching an experimental drug called dupilumab (called "study drug"). The study is focused on children with active eosinophilic esophagitis (EoE; an inflammatory disease of the esophagus) which impacts feeding…
- Trial name
- EoE-TOTs (NCT07112378)
- Testing
- dupilumab
- Where
- 13 sites in United States
- Volunteers
- 20 people
- Sponsor
- Regeneron Pharmaceuticals
Gastroesophageal Reflux Disease
The Study to Describe Symptom Control and Impact on Daily Life in Gastroesophageal Reflux Disease (GERD) Patients
The purpose of this study is to evaluate symptoms control and impact on daily life from patients perspective using specific GERD Impact Scale(GIS) questionnaire.
- Trial name
- NCT01200550
- Where
- 23 sites in Bosnia and Herzegovina
- Volunteers
- 1,233 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux Disease (GERD)
Performance and Safety of Afluxin® in Patients With Gastroesophageal Reflux Disease
Gastroesophageal Reflux Disease (GERD) is a chronic condition in which stomach acid flows back into the esophagus, causing irritation and inflammation.
- Trial name
- ARMOR (NCT06984484)
- Testing
- Afluxin®
- Where
- 7 sites in Italy
- Volunteers
- 208 people
- Sponsor
- Devintec Sagl
Functional Gastrointestinal Disorders
Study to Learn More About the Stomach and Intestine Complaints of Children Aged From 3 to 14 Years
In this observational study, researchers want to gain more information on children suffering from abnormal stomach and intestine function (based on the Rome criteria) and treated Iberogast.
- Trial name
- NCT04029376
- Testing
- Iberogast®
- Where
- Germany
- Volunteers
- 1,032 people
- Sponsor
- Bayer
Gastric Ulcer, Duodenal Ulcer
Comparative Efficacy & Safety Study of Esomeprazole Versus Placebo for the Prevention of Gastric and Duodenal Ulcers With NSAID
The purpose of this study is to assess the efficacy of esomeprazole (D961H) 20 mg versus placebo once daily for up to 24 weeks of treatment involving patients with a history of gastric and/or duodenal ulcers receiving daily…
- Conditions
- Gastric Ulcer, Duodenal Ulcer, Rheumatoid Arthritis, Osteoarthritis
- Trial name
- NCT00542789
- Testing
- Esomeprazole
- Where
- 39 sites in Japan
- Volunteers
- 343 people
- Sponsor
- AstraZeneca
Gastroparesis, Diabetes Mellitus, Type 1
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
The purpose of this study is to test the safety and effectiveness of two dosage levels (10mg and 20mg) of TZP-102 compared to placebo (capsule that looks like the study drug but contains no active drug), administered once-daily…
- Conditions
- Gastroparesis, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01452815
- Testing
- 10mg TZP-102, 20mg TZP-102
- Where
- 52 sites in United States, Belgium and 6 more
- Volunteers
- 201 people
- Sponsor
- Tranzyme, Inc.
Gastroesophageal Reflux
Study on the Tolerance and Efficacy of a New Anti Regurgitation Formula
The aim of this study is to evaluate the efficacy of a new thickened formula on regurgitation.
- Trial name
- SONAR (NCT02425423)
- Testing
- New thickened formula
- Where
- 3 sites in Belgium, France
- Volunteers
- 100 people
- Sponsor
- United Pharmaceuticals
Gastric Ulcer
Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) Naproxen
This study uses a randomized, double-blind, controlled design to demonstrate that PN400 (esomeprazole and naproxen) is more effective in reducing the occurrence of gastroduodenal ulcers, dyspepsia, and heartburn in subjects at…
- Trial name
- NCT00527787
- Testing
- PN400 (VIMOVO), Naproxen
- Where
- United States
- Volunteers
- 434 people
- Sponsor
- POZEN
Reflux Oesophagitis
Effect of Repeated Doses of YF476, Omeprazole and Placebo on Stomach Acidity in Healthy Volunteers
The objectives of this study were: To compare repeated doses of YF476 at 2 dose levels, placebo and omeprazole with respect to their effect on basal- and food- stimulated gastric pH in healthy volunteers.
- Trial name
- NCT01599858
- Testing
- YF476, Omeprazole
- Where
- United Kingdom
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Trio Medicines Ltd.
Locally Advanced or Metastatic Solid Tumors, PTEN Loss or Low Expression
A Single-arm, Open-label, Multicenter, Phase Ib/II Clinical Trial of CVL237 Tablets in Combination With Serplulimab Injection for the Treatment of Advanced Solid Tumors With PTEN Loss or Low Expression
This is a single-arm, open-label, multicenter, Phase Ib/II clinical trial of CVL237 tablets in combination with serplulimab injection for the treatment of advanced solid tumors with PTEN loss or low expression
- Trial name
- NCT07446049
- Testing
- CVL237 tablets
- Volunteers
- 180 people
- Sponsor
- Convalife (Shanghai) Co., Ltd.
Dysphagia, Malnutrition
IDDSI Nutritional Drink for Dysphagia Study
This study will evaluate the gastrointestinal (GI) tolerance, compliance , acceptability and safety of a ready-to-use oral nutritional supplement drink for patients with dysphagia.
- Trial name
- NCT03679078
- Testing
- IDDSI nutritional supplement drink
- Where
- 8 sites in United Kingdom
- Volunteers
- 40 people
- Sponsor
- Nutricia UK Ltd
Breast Cancer, Endometrial Cancer
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway…
- Conditions
- Breast Cancer, Endometrial Cancer, Ovarian Cancer, Lung Squamous Cell Carcinoma
- Trial name
- NCT07109726
- Testing
- TER-2013, Fulvestrant injection
- Where
- 25 sites in United States, Ireland and 3 more
- Volunteers
- 248 people
- Sponsor
- Terremoto Biosciences Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.